Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 62

Results For "2022"

1455 News Found

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
News | December 20, 2022

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years


Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
Drug Approval | December 20, 2022

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting


Sun Pharmaceutical receives warning letter from USFDA for Halol facility
Drug Approval | December 19, 2022

Sun Pharmaceutical receives warning letter from USFDA for Halol facility

The Halol facility was placed under Import Alert by USFDA.


Mandaviya asserts govt's commitment towards improving access to quality medical education
Policy | December 16, 2022

Mandaviya asserts govt's commitment towards improving access to quality medical education

India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014


China aims to lead next bio revolution in advanced biologics, says GlobalData
News | December 15, 2022

China aims to lead next bio revolution in advanced biologics, says GlobalData

China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production


Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
Clinical Trials | December 15, 2022

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study


Briefs: Jubilant Pharmova and Apollo Hospitals Enterprise
News | December 15, 2022

Briefs: Jubilant Pharmova and Apollo Hospitals Enterprise

The company will submit an action plan on the observations and will engage with US FDA for next steps.


De Nora and Aclarity sign agreement to deploy PFAS destroying technology
News | December 15, 2022

De Nora and Aclarity sign agreement to deploy PFAS destroying technology

The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally


Peter Bains appointed Additional Director of Biocon
People | December 13, 2022

Peter Bains appointed Additional Director of Biocon

He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels


Alembic receives USFDA final Approval for Desonide Cream
Drug Approval | December 12, 2022

Alembic receives USFDA final Approval for Desonide Cream

Desonide Cream, 0.05%, has an estimated market size of US $12 million for twelve months ending Sep 2022 according to IQVIA